{"transactions":[{"id":860981,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:48:18.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":26921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Holdings include unvested restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include unvested restricted stock units (\"RSUs\")."}],"balance_after":101926,"source":{"system":"sec-edgar","filing":"0001193125-26-092253","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000119312526092253/ownership.xml","form_type":"4"}},{"id":862297,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62884,"kind":"person","name":"Jacroux Richard","position":1,"cik":"0002033818","reported_name":"Jacroux Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:48:01.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":13461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Holdings include unvested restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Holdings include unvested restricted stock units (\"RSUs\")."}],"balance_after":33461,"source":{"system":"sec-edgar","filing":"0001193125-26-092251","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033818/000119312526092251/ownership.xml","form_type":"4"}},{"id":932646,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-24T00:44:04.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":60324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":136589,"source":{"system":"sec-edgar","filing":"0001193125-26-021415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000119312526021415/ownership.xml","form_type":"4"}},{"id":931954,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-24T00:43:37.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":60324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Holdings include unvested restricted stock units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026."}],"balance_after":65710,"source":{"system":"sec-edgar","filing":"0001193125-26-021414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000119312526021414/ownership.xml","form_type":"4"}},{"id":932411,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-24T00:43:04.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":60324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested RSUs."}],"balance_after":65709,"source":{"system":"sec-edgar","filing":"0001193125-26-021412","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000119312526021412/ownership.xml","form_type":"4"}},{"id":932526,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62884,"kind":"person","name":"Jacroux Richard","position":1,"cik":"0002033818","reported_name":"Jacroux Richard","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-23T19:43:22.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001193125-26-021413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2033818/000119312526021413/ownership.xml","form_type":"4"}},{"id":932058,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-23T19:42:44.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027."}],"balance_after":75005,"source":{"system":"sec-edgar","filing":"0001193125-26-021411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000119312526021411/ownership.xml","form_type":"4"}},{"id":1018815,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2025-10-16T01:54:17.000Z","date":"2025-10-10","kind":"grant","planned":false,"acquired":true,"shares":141644,"price":7.06,"value":1000006.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock."}],"balance_after":141644,"derivative":{"exercise_price":6.81,"exercise_date":"2025-10-15","expiration_date":"2030-10-15","underlying":"Common Stock","underlying_shares":141644},"source":{"system":"sec-edgar","filing":"0001193125-25-240662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000119312525240662/ownership.xml","form_type":"4"}},{"id":1018814,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-16T01:54:17.000Z","date":"2025-10-10","kind":"grant","planned":false,"acquired":true,"shares":70822,"price":7.06,"value":500003.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares of Common Stock and Warrants were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Common Stock was purchased together with Warrants exercisable for two shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested restricted stock units."}],"balance_after":76265,"source":{"system":"sec-edgar","filing":"0001193125-25-240662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000119312525240662/ownership.xml","form_type":"4"}},{"id":1097970,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T10:26:33.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026."}],"balance_after":5385,"source":{"system":"sec-edgar","filing":"0000950170-25-091888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000095017025091888/ownership.xml","form_type":"4"}},{"id":1097543,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T10:25:48.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026."}],"balance_after":5386,"source":{"system":"sec-edgar","filing":"0000950170-25-091887","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000095017025091887/ownership.xml","form_type":"4"}},{"id":1098313,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-01T10:25:00.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":5384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026."}],"balance_after":5443,"source":{"system":"sec-edgar","filing":"0000950170-25-091885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000095017025091885/ownership.xml","form_type":"4"}},{"id":1413497,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":2859,"kind":"organization","name":"UBS Group AG","position":1,"cik":"0001610520","reported_name":"UBS Group AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Market maker/broker-dealer"}}],"security":"Common Stock","published_at":"2024-09-05T19:28:10.000Z","date":"2024-08-27","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Subsidiary"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024.  Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares.  When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares.  Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary"}],"balance_after":146012,"source":{"system":"sec-edgar","filing":"0001610520-24-000153","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610520/000161052024000153/primary_doc.xml","form_type":"4/A","original_submission_date":"2024-08-29"}},{"id":1419724,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":2859,"kind":"organization","name":"UBS Group AG","position":1,"cik":"0001610520","reported_name":"UBS Group AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T20:30:01.000Z","date":"2024-08-27","kind":"purchase","planned":false,"acquired":true,"shares":3715,"price":0.5523,"value":2051.7945,"ownership":{"direct":false,"nature":"By Subsidiary"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Statement is filed jointly by UBS Group AG for the benefit and\non behalf of UBS Securities LLC\nand UBS Financial Services Inc., a wholly owned subsidiary of UBS Group"}],"balance_after":146012,"source":{"system":"sec-edgar","filing":"0001610520-24-000151","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610520/000161052024000151/primary_doc.xml","form_type":"4"}},{"id":1622748,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-02-23T22:00:45.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025."}],"balance_after":600,"derivative":{"exercise_price":1.59,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001209191-24-003899","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919124003899/doc4.xml","form_type":"4"}},{"id":1621676,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-02-23T22:00:41.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025."}],"balance_after":600,"derivative":{"exercise_price":1.59,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001209191-24-003900","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919124003900/doc4.xml","form_type":"4"}},{"id":1623247,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-02-23T22:00:39.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025."}],"balance_after":600,"derivative":{"exercise_price":1.59,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001209191-24-003901","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919124003901/doc4.xml","form_type":"4"}},{"id":1622120,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-02-23T17:00:32.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 2, 2024 pursuant to the Issuer's Non-Employee Director Compensation Policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award becomes exercisable in three equal annual installments beginning January 2, 2025."}],"balance_after":600,"derivative":{"exercise_price":1.59,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":600},"source":{"system":"sec-edgar","filing":"0001209191-24-003902","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919124003902/doc4.xml","form_type":"4"}},{"id":1882060,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2023-05-22T11:30:06.000Z","date":"2023-05-18","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":1.65,"value":24750.0,"ownership":{"direct":true},"balance_after":34139,"source":{"system":"sec-edgar","filing":"0001209191-23-031298","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919123031298/doc4.xml","form_type":"4"}},{"id":1906783,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2023-05-03T20:07:29.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":41667,"price":0.01,"value":416.67,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Represents warrants purchased in the Offering. The warrants were offered and sold at the rate of one warrant to purchase one share for every two shares of common stock purchased in the Offering."}],"balance_after":41667,"derivative":{"exercise_price":1.4,"exercise_date":"2023-05-02","expiration_date":"2028-05-02","underlying":"Common Stock","underlying_shares":41667},"source":{"system":"sec-edgar","filing":"0001209191-23-026925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919123026925/doc4.xml","form_type":"4"}},{"id":1906782,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-03T20:07:29.000Z","date":"2023-05-02","kind":"purchase","planned":false,"acquired":true,"shares":83333,"price":1.2,"value":99999.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares purchased in the Registrant's underwritten public offering that closed May 2, 2023 (the \"Offering\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The public offering price for each set of two shares of common stock and accompanying warrant to purchase one share of common stock was $2.41 per set of securities, yielding an effective price of $1.20 per share and $0.01 per warrant in the Offering."}],"balance_after":102434,"source":{"system":"sec-edgar","filing":"0001209191-23-026925","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919123026925/doc4.xml","form_type":"4"}},{"id":2038631,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-02-02T01:30:39.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":6746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":6746,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":6746},"source":{"system":"sec-edgar","filing":"0001209191-23-006052","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919123006052/doc4.xml","form_type":"4"}},{"id":2038205,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-02-02T01:30:32.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":9634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":9634,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":9634},"source":{"system":"sec-edgar","filing":"0001209191-23-006050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919123006050/doc4.xml","form_type":"4"}},{"id":2038974,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-02-02T01:30:27.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":9621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":9621,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":9621},"source":{"system":"sec-edgar","filing":"0001209191-23-006049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919123006049/doc4.xml","form_type":"4"}},{"id":2038204,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117421,"kind":"person","name":"Pestrikova Irina","position":1,"cik":"0001868216","reported_name":"Pestrikova Irina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Director, Finance"}}],"security":"Stock Options","published_at":"2023-02-02T01:30:20.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":8000,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-006048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919123006048/doc4.xml","form_type":"4"}},{"id":2038203,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Options","published_at":"2023-02-02T01:30:15.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":68066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":68066,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":68066},"source":{"system":"sec-edgar","filing":"0001209191-23-006047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919123006047/doc4.xml","form_type":"4"}},{"id":2038339,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-02-01T20:30:36.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":9621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":9621,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":9621},"source":{"system":"sec-edgar","filing":"0001209191-23-006051","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919123006051/doc4.xml","form_type":"4"}},{"id":2038568,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2023-02-01T20:30:11.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":69531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning January 30, 2024."}],"balance_after":69531,"derivative":{"exercise_price":4.02,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":69531},"source":{"system":"sec-edgar","filing":"0001209191-23-006046","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919123006046/doc4.xml","form_type":"4"}},{"id":2087427,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2022-12-13T21:00:20.000Z","date":"2022-12-09","kind":"purchase","acquired":true,"shares":1500,"price":3.4,"value":5100.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On December 9, 2022, the Issuer effected a 1-for-20 reverse stock split (the \"Reverse Stock Split\") of its outstanding Common Stock. The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":19139,"source":{"system":"sec-edgar","filing":"0001209191-22-060895","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122060895/doc4.xml","form_type":"4"}},{"id":2103225,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-28T17:00:17.000Z","date":"2022-11-23","kind":"purchase","acquired":true,"shares":10000,"price":0.17,"value":1700.0,"ownership":{"direct":true},"balance_after":162857,"source":{"system":"sec-edgar","filing":"0001209191-22-058875","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919122058875/doc4.xml","form_type":"4"}},{"id":2174649,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2022-08-24T12:57:22.000Z","date":"2022-08-22","kind":"purchase","acquired":true,"shares":20000,"price":0.27,"value":5400.0,"ownership":{"direct":true},"balance_after":352775,"source":{"system":"sec-edgar","filing":"0001209191-22-047298","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122047298/doc4.xml","form_type":"4"}},{"id":2174742,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-24T08:55:31.000Z","date":"2022-08-22","kind":"purchase","acquired":true,"shares":20000,"price":0.26,"value":5200.0,"ownership":{"direct":true},"balance_after":152857,"source":{"system":"sec-edgar","filing":"0001209191-22-047297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919122047297/doc4.xml","form_type":"4"}},{"id":2250823,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2022-05-31T12:46:59.000Z","date":"2022-05-26","kind":"purchase","acquired":true,"shares":25000,"price":0.21,"value":5250.0,"ownership":{"direct":true},"balance_after":332775,"source":{"system":"sec-edgar","filing":"0001209191-22-032746","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122032746/doc4.xml","form_type":"4"}},{"id":2259359,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2022-05-23T20:30:16.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":25000,"price":0.22,"value":5500.0,"ownership":{"direct":true},"balance_after":307775,"source":{"system":"sec-edgar","filing":"0001209191-22-031319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122031319/doc4.xml","form_type":"4"}},{"id":2263764,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-05-19T07:00:11.000Z","date":"2022-05-17","kind":"purchase","acquired":true,"shares":5100,"price":0.19,"value":969.0,"ownership":{"direct":true},"balance_after":97191,"source":{"system":"sec-edgar","filing":"0001209191-22-030307","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919122030307/doc4.xml","form_type":"4"}},{"id":2267560,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T16:14:45.000Z","date":"2022-05-16","kind":"purchase","acquired":true,"shares":100000,"price":0.1963,"value":19630.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1911 to $0.1963, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."}],"balance_after":132857,"source":{"system":"sec-edgar","filing":"0001209191-22-029593","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919122029593/doc4.xml","form_type":"4"}},{"id":2313830,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2022-03-30T21:16:03.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":186430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":186430,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":186430},"source":{"system":"sec-edgar","filing":"0001209191-22-021625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122021625/doc4.xml","form_type":"4"}},{"id":2313829,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Options","published_at":"2022-03-30T21:15:56.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":698102,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":698102,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":698102},"source":{"system":"sec-edgar","filing":"0001209191-22-021624","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122021624/doc4.xml","form_type":"4"}},{"id":2314394,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-03-30T21:15:34.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":109323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":109323,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":109323},"source":{"system":"sec-edgar","filing":"0001209191-22-021621","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919122021621/doc4.xml","form_type":"4"}},{"id":2313828,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117421,"kind":"person","name":"Pestrikova Irina","position":1,"cik":"0001868216","reported_name":"Pestrikova Irina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Director, Finance"}}],"security":"Stock Options","published_at":"2022-03-30T21:15:32.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":41500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":41500,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":41500},"source":{"system":"sec-edgar","filing":"0001209191-22-021620","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122021620/doc4.xml","form_type":"4"}},{"id":2313827,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-03-30T21:15:24.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":109492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":109492,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":109492},"source":{"system":"sec-edgar","filing":"0001209191-22-021619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122021619/doc4.xml","form_type":"4"}},{"id":2314278,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-03-30T21:15:14.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":74500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":74500,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":74500},"source":{"system":"sec-edgar","filing":"0001209191-22-021618","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919122021618/doc4.xml","form_type":"4"}},{"id":2314233,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2022-03-30T17:15:42.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":713132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":713132,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":713132},"source":{"system":"sec-edgar","filing":"0001209191-22-021622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919122021622/doc4.xml","form_type":"4"}},{"id":2314059,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-03-30T17:15:41.000Z","date":"2022-03-28","kind":"grant","acquired":true,"shares":109323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning March 28, 2023."}],"balance_after":109323,"derivative":{"exercise_price":0.38,"expiration_date":"2032-03-28","underlying":"Common Stock","underlying_shares":109323},"source":{"system":"sec-edgar","filing":"0001209191-22-021623","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919122021623/doc4.xml","form_type":"4"}},{"id":2450880,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-01-04T22:06:24.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.74,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-000957","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919122000957/doc4.xml","form_type":"4"}},{"id":2447199,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-01-04T22:05:15.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.74,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-000954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919122000954/doc4.xml","form_type":"4"}},{"id":2449797,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-01-04T22:03:07.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.74,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-000951","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919122000951/doc4.xml","form_type":"4"}},{"id":2447910,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-01-04T17:07:49.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.74,"exercise_date":"2023-01-03","expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-22-000961","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919122000961/doc4.xml","form_type":"4"}},{"id":2561453,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-09-22T20:05:13.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":22815,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":316525,"source":{"system":"sec-edgar","filing":"0001209191-21-057234","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121057234/doc4.xml","form_type":"4"}},{"id":2588435,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T20:15:10.000Z","date":"2021-08-26","kind":"sale","acquired":false,"shares":5000,"price":1.85,"value":9250.0,"ownership":{"direct":true},"balance_after":49068,"source":{"system":"sec-edgar","filing":"0001209191-21-053613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919121053613/doc4.xml","form_type":"4"}},{"id":2588434,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-08-27T20:15:10.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":45000,"price":1.83,"value":82350.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.81 to $1.84, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":54068,"source":{"system":"sec-edgar","filing":"0001209191-21-053613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919121053613/doc4.xml","form_type":"4"}},{"id":2658204,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117421,"kind":"person","name":"Pestrikova Irina","position":1,"cik":"0001868216","reported_name":"Pestrikova Irina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Director, Finance"}}],"security":"Stock Option","published_at":"2021-06-22T20:12:07.000Z","date":"2021-06-18","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning June 18, 2022."}],"balance_after":75000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-06-18","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-21-042378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121042378/doc4.xml","form_type":"4"}},{"id":2734199,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-04-30T20:22:50.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":22815,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units paid as a 2020 annual bonus by the Issuer to the Reporting Person, which fully vested upon grant."}],"balance_after":316525,"source":{"system":"sec-edgar","filing":"0001209191-21-029290","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121029290/doc4.xml","form_type":"4"}},{"id":2753773,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-04-07T20:16:52.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121025861/doc4.xml","form_type":"4"}},{"id":2754708,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-04-07T20:15:10.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919121025859/doc4.xml","form_type":"4"}},{"id":2754490,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-04-07T20:13:25.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025853","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919121025853/doc4.xml","form_type":"4"}},{"id":2753772,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Options","published_at":"2021-04-07T20:11:15.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121025850/doc4.xml","form_type":"4"}},{"id":2754231,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2021-04-07T20:10:35.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025849","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919121025849/doc4.xml","form_type":"4"}},{"id":2753771,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Options","published_at":"2021-04-07T20:08:40.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":50000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-025846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121025846/doc4.xml","form_type":"4"}},{"id":2753770,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-04-07T20:08:40.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":15000,"price":2.53,"value":37950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":259960,"source":{"system":"sec-edgar","filing":"0001209191-21-025846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121025846/doc4.xml","form_type":"4"}},{"id":2753769,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-04-07T20:08:40.000Z","date":"2021-03-29","kind":"sale","acquired":false,"shares":18750,"price":2.37,"value":44437.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":274960,"source":{"system":"sec-edgar","filing":"0001209191-21-025846","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121025846/doc4.xml","form_type":"4"}},{"id":2754030,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-04-07T16:18:02.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":25000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-025866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919121025866/doc4.xml","form_type":"4"}},{"id":2754371,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2021-04-07T16:05:10.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022."}],"balance_after":50000,"derivative":{"exercise_price":2.64,"expiration_date":"2031-04-05","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-21-025842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919121025842/doc4.xml","form_type":"4"}},{"id":2772079,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-03-25T21:01:02.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-023042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919121023042/doc4.xml","form_type":"4"}},{"id":2771626,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-03-25T21:00:55.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-023040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121023040/doc4.xml","form_type":"4"}},{"id":2772302,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-03-25T21:00:45.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-023038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919121023038/doc4.xml","form_type":"4"}},{"id":2771734,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-03-25T17:00:50.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a stock option award granted on January 4, 2021 pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":12000,"derivative":{"exercise_price":0.8,"exercise_date":"2022-01-04","expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-023039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919121023039/doc4.xml","form_type":"4"}},{"id":2906852,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-14T21:18:49.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":13696,"price":1.1,"value":15065.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan."}],"balance_after":1580,"source":{"system":"sec-edgar","filing":"0001209191-21-003597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121003597/doc4.xml","form_type":"4"}},{"id":2906851,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-14T21:18:49.000Z","date":"2021-01-12","kind":"sale","acquired":false,"shares":6304,"price":1.05,"value":6619.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan."}],"balance_after":15276,"source":{"system":"sec-edgar","filing":"0001209191-21-003597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121003597/doc4.xml","form_type":"4"}},{"id":2911729,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-09T00:11:44.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":8731,"price":0.94,"value":8207.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units."}],"balance_after":21580,"source":{"system":"sec-edgar","filing":"0001209191-21-002828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121002828/doc4.xml","form_type":"4"}},{"id":2912016,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":62784,"kind":"person","name":"Tokman Alexander Y","position":1,"cik":"0001334483","reported_name":"Tokman Alexander Y","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-01-08T19:10:55.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":10000,"price":0.9,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020."}],"balance_after":32857,"source":{"system":"sec-edgar","filing":"0001209191-21-002827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1334483/000120919121002827/doc4.xml","form_type":"4"}},{"id":2915472,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T00:15:07.000Z","date":"2021-01-06","kind":"sale","acquired":false,"shares":34900,"price":0.9,"value":31410.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020."}],"balance_after":80003,"source":{"system":"sec-edgar","filing":"0001209191-21-002370","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919121002370/doc4.xml","form_type":"4"}},{"id":2915471,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T00:15:07.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":100,"price":0.9,"value":90.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units which were granted to the Reporting Person on April 9, 2020."}],"balance_after":114903,"source":{"system":"sec-edgar","filing":"0001209191-21-002370","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919121002370/doc4.xml","form_type":"4"}},{"id":2914526,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-01-07T00:15:07.000Z","date":"2021-01-06","kind":"sale","acquired":false,"shares":11269,"price":0.94,"value":10592.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units."}],"balance_after":30311,"source":{"system":"sec-edgar","filing":"0001209191-21-002371","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919121002371/doc4.xml","form_type":"4"}},{"id":2935764,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-12-21T12:00:09.000Z","date":"2020-12-17","kind":"sale","acquired":false,"shares":25000,"price":0.73,"value":18250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.73 to $0.75, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested restricted stock units."}],"balance_after":41580,"source":{"system":"sec-edgar","filing":"0001209191-20-064584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120064584/doc4.xml","form_type":"4"}},{"id":2953514,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-08T07:04:44.000Z","date":"2020-12-04","kind":"sale","acquired":false,"shares":71519,"price":0.83,"value":59360.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan in order to pay the tax liability associated with the vesting of restricted stock units  which were granted to the Reporting Person on April 9, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested restricted stock units."}],"balance_after":92091,"source":{"system":"sec-edgar","filing":"0001209191-20-062113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120062113/doc4.xml","form_type":"4"}},{"id":2979329,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-11-16T21:01:43.000Z","date":"2020-11-13","kind":"sale","acquired":false,"shares":10000,"price":0.81,"value":8100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.83, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested restricted stock units."}],"balance_after":66580,"source":{"system":"sec-edgar","filing":"0001209191-20-058450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120058450/doc4.xml","form_type":"4"}},{"id":3000043,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-26T21:14:49.000Z","date":"2020-10-22","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in three equal annual installments beginning on October 22, 2021."}],"balance_after":50000,"derivative":{"exercise_price":0.73,"expiration_date":"2030-10-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-055831","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919120055831/doc4.xml","form_type":"4"}},{"id":3012383,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":128621,"kind":"person","name":"Maloberti Renaud Bertrand","position":1,"cik":"0001744025","reported_name":"Maloberti Renaud Bertrand","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2020-10-05T11:22:40.000Z","date":"2020-10-01","kind":"sale","acquired":false,"shares":10000,"price":0.72,"value":7200.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a 10b5-1 trading plan to pay withholding taxes due in connection with the vesting of certain restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.72 to $0.74, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes unvested restricted stock units."}],"balance_after":76580,"source":{"system":"sec-edgar","filing":"0001209191-20-053429","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120053429/doc4.xml","form_type":"4"}},{"id":3077100,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-07-23T12:00:08.000Z","date":"2020-07-21","kind":"other","acquired":false,"shares":100503,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-10","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":100503},"source":{"system":"sec-edgar","filing":"0001209191-20-043430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919120043430/doc4.xml","form_type":"4"}},{"id":3077099,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-23T12:00:08.000Z","date":"2020-07-21","kind":"other","acquired":true,"shares":100503,"price":0.87,"value":87437.61,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Included unvested restricted stock units."}],"balance_after":382012,"source":{"system":"sec-edgar","filing":"0001209191-20-043430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919120043430/doc4.xml","form_type":"4"}},{"id":3081424,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Warrants","published_at":"2020-07-16T20:06:11.000Z","date":"2020-07-15","kind":"other","acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24252,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001209191-20-042615","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120042615/doc4.xml","form_type":"4"}},{"id":3081423,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2020-07-16T20:06:11.000Z","date":"2020-07-15","kind":"other","acquired":true,"shares":26000,"price":0.87,"value":22620.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":293710,"source":{"system":"sec-edgar","filing":"0001209191-20-042615","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120042615/doc4.xml","form_type":"4"}},{"id":3100485,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2020-06-24T12:23:36.000Z","date":"2020-06-23","kind":"other","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6056,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-038682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/doc4.xml","form_type":"4"}},{"id":3100484,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-24T12:23:36.000Z","date":"2020-06-23","kind":"other","acquired":true,"shares":5000,"price":0.87,"value":4350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":69243,"source":{"system":"sec-edgar","filing":"0001209191-20-038682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120038682/doc4.xml","form_type":"4"}},{"id":3100851,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants","published_at":"2020-06-24T12:22:41.000Z","date":"2020-06-23","kind":"other","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5051,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-038681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120038681/doc4.xml","form_type":"4"}},{"id":3100850,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-24T12:22:41.000Z","date":"2020-06-23","kind":"other","acquired":true,"shares":5000,"price":0.87,"value":4350.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":115003,"source":{"system":"sec-edgar","filing":"0001209191-20-038681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120038681/doc4.xml","form_type":"4"}},{"id":3100935,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants","published_at":"2020-06-24T08:21:51.000Z","date":"2020-06-23","kind":"other","acquired":false,"shares":2874,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2152,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","expiration_date":"2024-12-11","underlying":"Common Stock","underlying_shares":2874},"source":{"system":"sec-edgar","filing":"0001209191-20-038680","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120038680/doc4.xml","form_type":"4"}},{"id":3100934,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-24T08:21:51.000Z","date":"2020-06-23","kind":"other","acquired":true,"shares":2874,"price":0.87,"value":2500.38,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":163610,"source":{"system":"sec-edgar","filing":"0001209191-20-038680","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120038680/doc4.xml","form_type":"4"}},{"id":3114254,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T11:39:26.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":9.618,"price":1143.68,"value":10999.91424,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":11386},"source":{"system":"sec-edgar","filing":"0001209191-20-035439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120035439/doc4.xml","form_type":"4"}},{"id":3114253,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":68857,"kind":"person","name":"Harsh Michael","position":1,"cik":"0001706155","reported_name":"Harsh Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-10T11:39:26.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":11386,"price":0.87,"value":9905.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":64243,"source":{"system":"sec-edgar","filing":"0001209191-20-035439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120035439/doc4.xml","form_type":"4"}},{"id":3114746,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T11:38:00.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":8.744,"price":1143.68,"value":10000.33792,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001209191-20-035438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120035438/doc4.xml","form_type":"4"}},{"id":3114745,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":45655,"kind":"person","name":"Wells David R.","position":1,"cik":"0001480371","reported_name":"Wells David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-10T11:38:00.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":10350,"price":0.87,"value":9004.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":110003,"source":{"system":"sec-edgar","filing":"0001209191-20-035438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480371/000120919120035438/doc4.xml","form_type":"4"}},{"id":3114252,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T11:37:16.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":43.719,"price":1143.68,"value":50000.54592,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":51747},"source":{"system":"sec-edgar","filing":"0001209191-20-035437","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120035437/doc4.xml","form_type":"4"}},{"id":3114251,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":113238,"kind":"person","name":"Thornton Michael Milos","position":1,"cik":"0001706297","reported_name":"Thornton Michael Milos","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2020-06-10T11:37:16.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":51747,"price":0.87,"value":45019.89,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":267710,"source":{"system":"sec-edgar","filing":"0001209191-20-035437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681682/000120919120035437/doc4.xml","form_type":"4"}},{"id":3114879,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2020-06-10T07:36:29.000Z","date":"2020-06-08","kind":"exercise","acquired":false,"shares":4.372,"price":1143.68,"value":5000.16896,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series A Convertible Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":0.87,"exercise_date":"2019-12-11","underlying":"Common Stock","underlying_shares":5175},"source":{"system":"sec-edgar","filing":"0001209191-20-035436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120035436/doc4.xml","form_type":"4"}},{"id":3114878,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":117424,"kind":"person","name":"Michelon Francois Roger","position":1,"cik":"0001691470","reported_name":"Michelon Francois Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-06-10T07:36:29.000Z","date":"2020-06-08","kind":"exercise","acquired":true,"shares":5175,"price":0.87,"value":4502.25,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":160736,"source":{"system":"sec-edgar","filing":"0001209191-20-035436","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691470/000120919120035436/doc4.xml","form_type":"4"}},{"id":3117226,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T11:27:45.000Z","date":"2020-06-08","kind":"purchase","acquired":true,"shares":5000,"price":0.92,"value":4600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested restricted stock units."}],"balance_after":281509,"source":{"system":"sec-edgar","filing":"0001209191-20-035185","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919120035185/doc4.xml","form_type":"4"}},{"id":3129262,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":32915,"kind":"person","name":"Basenese Lou","position":1,"cik":"0001809482","reported_name":"Basenese Lou","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-01T10:27:43.000Z","date":"2020-05-29","kind":"purchase","acquired":true,"shares":10000,"price":0.9,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes unvested restricted stock units."}],"balance_after":99068,"source":{"system":"sec-edgar","filing":"0001209191-20-033102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1809482/000120919120033102/doc4.xml","form_type":"4"}},{"id":3131094,"issuer":{"id":8083,"kind":"organization","name":"ENDRA Life Sciences Inc."},"owners":[{"id":33202,"kind":"person","name":"DIGIANDOMENICO ANTHONY","position":1,"cik":"0001083544","reported_name":"DIGIANDOMENICO ANTHONY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T10:49:56.000Z","date":"2020-05-28","kind":"purchase","acquired":true,"shares":5000,"price":0.9,"value":4500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.88 to $0.94, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes unvested restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The balance reflects an adjustment to correct a computational error in column 5 of the reporting person's Form 4 filed December 11, 2019, which stated 199,226 but should have stated 218,652."}],"balance_after":276509,"source":{"system":"sec-edgar","filing":"0001209191-20-032827","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1083544/000120919120032827/doc4.xml","form_type":"4"}}],"next_cursor":"2020-05-29T10:49:56.000000Z,3131094"}